[{"id":"0b31801d-bfeb-43b6-a0a2-863055f3325d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310541","created_at":"2021-01-19T14:57:57.429Z","updated_at":"2024-07-02T16:35:48.874Z","phase":"Phase 1","brief_title":"AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations","source_id_and_acronym":"NCT03310541","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AKT2","pipe":" | ","alterations":" AKT3 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/11/2017","start_date":" 10/11/2017","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 05/03/2023","study_completion_date":" 05/03/2023","last_update_posted":"2023-05-05"}]